<SEC-DOCUMENT>0001776985-24-000073.txt : 20240816
<SEC-HEADER>0001776985-24-000073.hdr.sgml : 20240816
<ACCEPTANCE-DATETIME>20240816065610
ACCESSION NUMBER:		0001776985-24-000073
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240816
FILED AS OF DATE:		20240816
DATE AS OF CHANGE:		20240816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		241214098

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kcombovaccineph23upd.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3302ccfff5ab42fe8c8d56fbf17932b2_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF AUGUST 2024</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">On August 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> 2024, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BioNTech SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Pfizer Inc.</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> announced top-line results from their Phase 3 clinical trial to evaluate the companies&#8217; combined </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">m</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">RNA </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The press release is attached hereto as Exhibit 99.1.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; August 16,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> 2024</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="ex99_120240816xbntxcombova.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age</a></font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_120240816xbntxcombova.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0db900948f9f4962b4a04309a06eb923_1"></div><div style="min-height:108pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:125%">Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.85pt">In a Phase 3 trial, Pfizer and BioNTech&#8217;s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.85pt">The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.85pt">The companies are evaluating adjustments to the candidate and will discuss next steps with health authorities </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.85pt">Pfizer also provides update on its separate Phase 2 second-generation trivalent influenza mRNA vaccine trial which showed encouraging data demonstrating robust immunogenicity against all strains compared to a standard of care influenza vaccine </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">NEW YORK and MAINZ, Germany, August 16, 2024 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212; Pfizer Inc. (NYSE&#58; PFE, &#8220;Pfizer&#8221;) </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">and </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech SE</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> (Nasdaq&#58; BNTX, &#8220;BioNTech&#8221;) today announced top-line results from their Phase 3 clinical trial to evaluate the companies&#8217; combined </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">m</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">RNA </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer&#8217;s mRNA-based influenza vaccine candidate with the companies&#8217; licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (&#8220;tIRV&#8221;) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Update on Phase 3 Pfizer and BioNTech Combination Vaccine Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Phase 3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">randomized, observer-blinded study (NCT06178991) enrolled more than 8,000 adults 18 through 64 years of age to evaluate the safety, tolerability, and immunogenicity of a single dose combination vaccine candidate against </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">influenza</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> and COVID-19</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. In this clinical trial, the vaccine candidate was compared to a licensed influenza vaccine and the companies&#8217; licensed COVID-19 vaccine given at the same visit. The primary immunogenicity objectives were to demonstrate that the antibody responses to influenza (hemagglutination inhibition, </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">HAI</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">) and to SARS-CoV-2 (neutralizing titer, </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NT</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">) elicited by the combination vaccine candidate were non-inferior (</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NI</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">) to standard of care (</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SOC</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">). Compared to a licensed influenza vaccine, the tIRV formulation was noteworthy for eliciting robust influenza A responses, including </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">continued trend of higher influenza A responses versus a licensed influenza vaccine,</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> while it showed lower geometric mean titers (&#8220;GMT&#8221;) and seroconversion against the influenza B strain. In addition, t</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">he formulation </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">demonstrated comparable responses against SARS-CoV-2 versus the companies&#8217; licensed COVID-19 vaccine. </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">No safety signals with the combination vaccine have been identified in an ongoing safety data review. Participants who received a licensed influenza and COVID-19 vaccine with co-administration continued to elicit robust immune responses against both influenza and COVID-19 with no safety signals identified to date.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;We are encouraged by the robust immunogenicity we saw with our combination vaccine against influenza A, which was similar to what we had seen for our initial quadrivalent influenza vaccine where we saw superior relative vaccine efficacy against a comparator flu vaccine,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Annaliesa Anderson, PhD, Senior Vice President and Head, Vaccine Research and Development at Pfizer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. &#8220;We are committed to developing vaccines that will reduce the burden of respiratory diseases and believe that combination vaccines are the most efficient way to do this. Today&#8217;s results provide insight and direction towards achieving this goal, and we remain optimistic about our combination COVID-19 and influenza program, for which we are evaluating the next steps.&#8221;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;We are dedicated to developing combination vaccines which provide broader protection against multiple respiratory diseases,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. &#8220;The insights gained from this combination vaccine trial are highly valuable and will play a crucial role in guiding the further development of Pfizer&#8217;s and our combination vaccine program against influenza and COVID-19. We are committed to drawing on our experience in developing mRNA-based vaccine candidates against multiple antigens and believe we can successfully accomplish this task in collaboration with our partner Pfizer.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Update on Pfizer's Phase 2 Second Generation Influenza Vaccine Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer&#8217;s Phase 2 trial (NCT06436703) to evaluate second-generation candidates against influenza was initiated earlier this year and enrolled 450 participants 18-64 years of age, who were randomized to receive investigational mRNA-based influenza vaccines or influenza vaccines approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). As previously stated, Pfizer announced positive top-line Phase 3 results from its first-generation quadrivalent (&#8220;qIRV&#8221;) vaccine candidate which achieved the first and only demonstration of efficacy for an mRNA vaccine in a group of study participants 18-64 years of age. The primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (&#8220;rVE&#8221;) compared to a licensed influenza vaccine was not met based on the number of cases accrued. Pfizer developed second-generation candidates with the goal of improving immunogenicity and potentially breadth of protection, including new tIRV formulations that matched updated recommendations by the World Health Organization (&#8220;WHO&#8221;) and the FDA&#8217;s Vaccines and Related Biological Products Advisory Committee (&#8220;VRBPAC&#8221;). The tIRV formulations elicited robust influenza A responses and B responses, including continued trend of higher influenza A responses versus a licensed influenza vaccine. There were no safety signals reported. Data from this Phase 2 trial for adults 65 years of age and older will become available at a later date. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer will also continue to evaluate its influenza vaccine program and discuss next steps with health authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About Influenza</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Influenza causes an estimated 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> and about $25 billion in economic loss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> in the U.S. each year. People 65 and older are at increased risk of serious complications from influenza, including hospitalization and death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Even when a vaccine matches circulating strains well, current influenza vaccines typically confer 40% to 60% protection each year, with even lower protection in years with poor matching of strains.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> The impact of influenza on racial and ethnic minority groups in the U.S. is even larger. Black Americans are nearly two times more likely than their white counterparts to be hospitalized for influenza while Latino and Indigenous Americans are 1.2 and 1.3 times more likely, respectively.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">5</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">With circulating influenza strains continually changing, predicting the best match for the next season&#8217;s vaccine is difficult for global health experts as those strains are chosen more than six months before the start of the influenza season that they target. The flexibility of mRNA technology and its rapid manufacturing could potentially allow better strain matches in future years, and in a pandemic influenza situation, mRNA technology could enable rapid, large-scale manufacturing of vaccines.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">INDICATION<br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">COMIRNATY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> (COVID-19 Vaccine, mRNA) is a vaccine for use in people 12 years of age and older to protect against coronavirus disease 2019 (COVID-19).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT SAFETY INFORMATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">You should&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">NOT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;receive COMIRNATY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;(COVID-19 Vaccine, mRNA) if you had a severe allergic reaction to a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine* or to any ingredient in these vaccines.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">*COMIRNATY (2023-2024 Formula) is made the same way as Pfizer-BioNTech COVID-19 Vaccine (Original monovalent) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent, but it encodes the spike protein of SARS-CoV-2 Omicron variant lineage XBB.1.5 (Omicron XBB.1.5).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Difficulty breathing</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Swelling of your face and throat</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">A fast heartbeat</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">A bad rash all over the body</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Dizziness and weakness</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines, including COMIRNATY and Pfizer-BioNTech COVID-19 vaccines. Myocarditis and pericarditis following COMIRNATY have occurred most commonly in adolescent males 12 through 17 years of age. In most of these individuals, symptoms began within a few days following vaccination. The chance of having this occur is very low. You should</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Chest pain</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Shortness of breath</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Feelings of having a fast-beating, fluttering, or pounding heart </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Fainting can happen after getting injectable vaccines including COMIRNATY. Your vaccination provider may ask you to sit or lie down for 15 minutes after receiving the vaccine</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">People with weakened immune systems may have a reduced immune response to COMIRNATY</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">COMIRNATY may not protect all vaccine recipients</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;padding-left:14.5pt">Before getting COMIRNATY, tell your vaccination provider about all of your medical conditions, including if you</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have any allergies</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have a fever</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have a bleeding disorder or are on a blood thinner</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">are immunocompromised or are on a medicine that affects the immune system</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">are pregnant, plan to become pregnant, or are breastfeeding</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have received another COVID-19 vaccine</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have ever fainted in association with an injection</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional side effects that have been reported with COMIRNATY or Pfizer-BioNTech COVID-19 vaccines include&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">Non-severe allergic reactions such as rash, itching, hives, or swelling of the face</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">Injection site reactions&#58; pain, swelling, redness, arm pain</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">General side effects&#58; tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, lymph nodes (lymphadenopathy), decreased appetite, diarrhea, vomiting, dizziness.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">These may not be all the possible side effects of COMIRNATY. Ask your healthcare provider about any side effects that concern you.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">You may report side effects to the FDA&#47;CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to www.vaers.hhs.gov&#47;reportevent.html. In addition, you can report side effects to Pfizer Inc. at 1-800-438-1985 or www.pfizersafetyreporting.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Please click here for full Prescribing Information and Patient Information for COMIRNATY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">AUTHORIZED USE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pfizer-BioNTech COVID-19 Vaccine&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2023-2024 Formula)* is FDA authorized under Emergency Use Authorization (EUA) to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.<br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">*Hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EMERGENCY USE AUTHORIZATION</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)&#8202;(1) of the FD&#38;C Act unless the declaration is terminated or authorization revoked sooner.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT SAFETY INFORMATION</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">A person should&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">NOT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;get Pfizer-BioNTech COVID-19 Vaccine if they had a severe allergic reaction after a previous dose of any Pfizer-BioNTech COVID-19 vaccine or to any ingredients in these vaccines</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">There is a remote chance that the vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, the vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination.&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">If your child experiences a severe allergic reaction, call 9-1-1, or go to the nearest hospital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. Signs of a severe allergic reaction can include&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, or dizziness and weakness</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following Pfizer-BioNTech COVID-19 vaccines have occurred most commonly in adolescent males 12 through 17 years of age. In most of these individuals, symptoms began within a few days following vaccination. The chance of having this occur is very low.&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Seek medical attention right away if your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Chest pain</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Shortness of breath or difficulty breathing</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Feelings of having a fast-beating, fluttering, or pounding heart</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional symptoms, particularly in children, may include&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Fainting</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Unusual and persistent irritability</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Unusual and persistent poor feeding</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Unusual and persistent fatigue or lack of energy</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Persistent vomiting</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Persistent pain in the abdomen</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Unusual and persistent cool, pale skin</font></div><div id="i0db900948f9f4962b4a04309a06eb923_4"></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Fainting can happen after getting injectable vaccines, including Pfizer-BioNTech COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">People with weakened immune systems may have a reduced immune response to Pfizer-BioNTech COVID-19 Vaccine</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Pfizer-BioNTech COVID-19 Vaccine may not protect everyone</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%;padding-left:14.5pt">Tell your vaccination provider about all of your child&#8217;s medical conditions, including if your child</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has any allergies</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has a fever</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has a bleeding disorder or is on a blood thinner</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">is immunocompromised or is on a medicine that affects the immune system</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">is pregnant or is breastfeeding</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has received another COVID-19 vaccine</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">has ever fainted in association with an injection</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Side effects that have been reported with Pfizer-BioNTech COVID-19 vaccines include&#58;</font></div><div id="i0db900948f9f4962b4a04309a06eb923_7"></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Severe allergic reactions</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Non-severe allergic reactions such as rash, itching, hives, or swelling of the face</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Myocarditis (inflammation of the heart muscle)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Pericarditis (inflammation of the lining outside the heart)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Injection site pain&#47;tenderness</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Tiredness</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Headache</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Muscle pain</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Arm pain</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Fainting in association with injection of the vaccine</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Chills</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Joint pain</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Fever</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Injection site swelling</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Injection site redness</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Nausea</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Feeling unwell</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Swollen lymph nodes (lymphadenopathy)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Decreased appetite</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Diarrhea</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Vomiting</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Dizziness</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Irritability<br></font></div><div id="i0db900948f9f4962b4a04309a06eb923_10"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">These may not be all the possible side effects. Serious and unexpected side effects may occur. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to www.vaers.hhs.gov&#47;reportevent.html. Please include &#8220;Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) EUA&#8221; in the first line of box #18 of the report form.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, individuals can report side effects to Pfizer Inc. at&#160;www.pfizersafetyreporting.com or by calling 1-800-438-1985.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Please click here for Pfizer-BioNTech COVID-19 Vaccine Healthcare Providers Fact Sheet and Vaccine Recipient and Caregiver EUA Fact Sheet. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About Pfizer&#58; Breakthroughs That Change Patients&#8217; Lives</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at&#8239;www.Pfizer.com. In addition, to learn more, please visit us on&#8239;www.Pfizer.com&#8239;and follow us on X at &#64;Pfizer and &#64;Pfizer News, LinkedIn, YouTube and like us on Facebook at&#8239;Facebook.com&#47;Pfizer.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pfizer Disclosure Notice </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The information contained in this release is as of August 16, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This release contains forward-looking information about Pfizer&#8217;s investigational modified RNA (modRNA) influenza vaccine candidates, potential next-generation mRNA flu and combination vaccine formulations, Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19, the flu and COVID&#47;flu combination programs, Pfizer&#8217;s respiratory vaccines portfolio and mRNA technology, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data, including uncertainties regarding the outcome of the ongoing Phase 2 trial of Pfizer&#8217;s second-generation influenza vaccine candidates in adults 65 years of age and older&#59; uncertainties regarding the future development of Pfizer&#8217;s mRNA influenza vaccine candidates, potential next-generation mRNA flu and combination vaccine formulations and Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19, including whether or when any such candidates will advance to future studies or phases of development&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; whether regulatory authorities will be satisfied with the design of and results from our clinical studies&#59; whether and when biologic license applications may be filed in any jurisdictions for Pfizer&#8217;s mRNA influenza vaccine candidates, potential next-generation mRNA flu or combination vaccine formulations or Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19 for any potential indications or for any other potential vaccine or product candidates&#59; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether Pfizer&#8217;s mRNA influenza vaccine candidates, potential next-generation mRNA flu or combination vaccine formulations, Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19 or any such other potential vaccine or product candidates will be commercially successful&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of Pfizer&#8217;s mRNA influenza vaccine candidates, potential next-generation mRNA flu or combination vaccine formulations, Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19 or any such other potential vaccine or product candidates, including development of products or therapies by other companies&#59; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities regarding Pfizer&#8217;s mRNA influenza vaccine candidates, potential next-generation mRNA flu or combination vaccine formulations, Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19 or any such other potential vaccine or product candidates and uncertainties regarding the commercial impact of any such recommendations&#59; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech&#59; the risk that we may not be able to successfully develop other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">vaccine formulations or combination vaccines&#59; the impact of COVID-19 on Pfizer&#8217;s business, operations and financial results&#59; and competitive developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at&#160;www.sec.gov&#160;and&#160;www.pfizer.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About BioNTech</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For more information, please visit www.BioNTech.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">BioNTech Forward-looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not be limited to, statements concerning&#58; the collaboration between BioNTech and Pfizer, including Pfizer&#8217;s investigational modified RNA (modRNA) influenza vaccine candidates, potential next-generation mRNA flu and combination vaccine formulations, and Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19, and mRNA technology&#59;&#59; qualitative assessments of available data and expectations of potential benefits, &#59; regulatory submissions and regulatory approvals or authorizations and expectations regarding manufacturing, distribution and supply&#59; expectations regarding anticipated changes in vaccine demand, including changes to the ordering environment&#59; and expected regulatory recommendations to adapt vaccines to address new strains, variants or sublineages. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#8217;s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data&#59; the nature of the clinical data, which is subject to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ongoing peer review, regulatory review and market interpretation&#59; uncertainties regarding potential next-generation mRNA flu and combination vaccine formulations and Pfizer&#8217;s and BioNTech&#8217;s mRNA-based combination vaccine candidate for influenza and COVID-19, including whether or when any such candidates will advance to future studies or phases of development&#59; the future commercial demand and medical need for an mRNA-based combination vaccine candidate for influenza and COVID-19&#59; the availability of raw materials to manufacture a vaccine&#59; vaccine formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery&#59; competition from other vaccines or related to BioNTech&#8217;s other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response&#59; the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations&#59; the timing of and BioNTech&#8217;s ability to obtain and maintain regulatory approval for BioNTech&#8217;s product candidates&#59; the ability of BioNTech&#8217;s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants&#59; BioNTech&#8217;s and its counterparties&#8217; ability to manage and source necessary energy resources&#59; BioNTech&#8217;s ability to identify research opportunities and discover and develop investigational medicines&#59; the ability and willingness of BioNTech&#8217;s third-party collaborators to continue research and development activities relating to BioNTech&#8217;s development candidates and investigational medicines&#59; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech and&#47;or its collaborators&#59; BioNTech&#8217;s and its collaborators&#8217; ability to commercialize and market products and, if approved, product candidates&#59; BioNTech&#8217;s ability to manage its development and expansion&#59; regulatory developments in the United States and other countries&#59; BioNTech&#8217;s ability to effectively scale production capabilities&#59; risks relating to the global financial system and markets&#59; and other factors not known to BioNTech at this time.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">You should review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in BioNTech's Report on Form 6-K for the period ended June 30, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#8217;s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Contacts<br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pfizer&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>Media Relations<br>+1 (212) 733-1226<br>PfizerMediaRelations&#64;pfizer.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investor Relations<br>+1 (212) 733-4848<br>IR&#64;pfizer.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">BioNTech&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>Media Relations<br>Jasmina Alatovic</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>+49 (0)6131 9084 1513<br>Media&#64;biontech.de</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investor Relations<br>Victoria Meissner, M.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">+1 617 528 8293<br>Investors&#64;biontech.de</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"># # #</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Disease Burden of Flu. Centers for Disease Control &#38; Prevention. Available at https&#58;&#47;&#47;www.cdc.gov&#47;flu&#47;about&#47;burden&#47;index.html</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Putri et al, Vaccine. 2018 Jun 22&#59;36(27)&#58;3960-3966. doi&#58; 10.1016&#47;j.vaccine.2018.05.057</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Flu &#38; People 65 Years and Older. Centers for Disease Control and Prevention. Available at&#58; Flu &#38; People 65 Years and Older &#124; CDC</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Vaccine Effectiveness&#58; How Well do the Flu Vaccines Work&#63; Centers for Disease Control &#38; Prevention. Available at https&#58;&#47;&#47;www.cdc.gov&#47;flu&#47;vaccines-work&#47;vaccineeffect.htm.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Flu Disparities Among Racial and Ethnic Minority Groups CDC. Available at https&#58;&#47;&#47;www.cdc.gov&#47;flu&#47;highrisk&#47;disparities-racial-ethnic-minority-groups.html.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M:.D)08%VA;KO3WIU7(E$CZJ*QO?4.#V,T8E*[S]GIYW0#_5ARYVKO-DG:XS
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M1/;]=*@@'?;RCO)G5$FU.D"K=$0"'B4$/ IX%"VJJ%2 FAI_F72&RT%I]X_
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M>H"'C(AX# WQ:!_JPV5+.??>U"TX2SN"(Z49:'!V\ 1M*= ,3ZCL>=H_R_U
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M-%Z/V2,=3GQ[/Q(W&Q\))T -A0IX'+=/H]5B% Z4;&BT2+DO!#/WYR6@V6R
MU3;%DR'$Y/2X850<_+M-%?CG[9-8HFP<LI^C-0E'D:2L'02NZ?O44#"!QSE@
M0W!KVM:%GL$H:#N_1IGN%10WOJ J?)RSJN95Z.S[$19K'APN,SS>F3#? UUP
MND;0;CRFW).%*&IX7MI8$\@TF&,Q.=,4"B/%X)'%8LU;^E$38FIRL#'M(A9*
M]DE>B]FM'(XO(+Z^ !/V&1YL%HL55F+PR IHN0A.C WA1%$RWHD[A"61.Z0Z
M 4LBMV-O;AQRVNLP.&E5Y9I"!3Q2M&.EH14'\A*D R."CG2_+U?<QYA]6K5H
M-99Z\L[.PN%VH<;8CF\R(O"F,A]D._FKX@\CJCH;6E.WB-!50\$''I] &X_'
MIOSV00R.9$#;^14J'K_A%_!8U/@"RG6OB6@\LS4',_;>L)XG(N+1946[\3A*
MM"^A4"9X;'L"'BGB-01&BL$CB\6:MUHL!IQ4SASKDTXI/HG<B$?*[CB8?PL/
M.QI$U@>+Q6*%DQ@\L@+XP#4KHA#SE UZ<_H5++VZ"PLEICW09Q'@.E.:!HU)
MCS&5HNI"!3Q2.DIV6RUV9E^3#AYI;#Z_>T%$NCH\+IX,(:RVH3Z<*+PCHAXI
MTE7F<[0B]@!^*KF+TIXF3*GDY <G>/RW9NQZ# PEHZ7G!U0VO8UBS4*_ ,CJ
MEE5HZ=T#TTB:B,;TY34']C[H@<M-X/$$2K5+4-3P/Q+!XX<P6N(P.=,<"B/%
MX)'%8LU;=![8G1.+]^(/2SUSD*U..(KHFESE.[IA=W.:-8O%"B\Q>&0%K"@B
MJEBOP[%'B2)E4O:;1ZK=LBQJ%^+K\S$T-2ZBK]10J(!'2D>YK2G"YHP(Z>"1
MHAWIK7!^9Z.(>F6%K@QC0TAH>(1O,B)%Z0.9SQ%%4>Y]&(^LMEI,.-1):PIV
M\$A@A0"+Q9J+INZ= C[Z SP6-OP)Q8W_B\?*./8/)<+F,(3E_'@"'L?083R)
M4@V#Q]\8*0:/+!9KWJI3?'2J+_[F]7W2?=NUMT\B2_'331.CG,G#8K'"3@P>
M60&IX>D)D1YYL3P#ZY-.B[HHLAV MV_LQV=WSXOF$Y2&Z?%Z5;FV4 &/E(Y"
MC64^33TG_=[\X]9Q7*W.1GU_)SMG(2Y*V<_O;! I^U3Z0.9S]/JU/=AR/PK)
MNE+5(IJ#'3S.:=K> XOUH:@M2""G1+/(#P#R.0$^=5W?P&A)P/BT1KGVZ;":
M'PP>__!(,7ADL5CS6&MG189-<;=.'(J71NV2&NCPBN*G$]"L-K:)-&OZ/A:+
MQ0HG,7AD!92\LUXXE8V?H..UVER?0*TY^S#I1YPN3D7C0)>JUQ@JX%$SH,?Q
MPCM8EWA*^KW9D'P&Z<V5Z!X=5 T(L_PC*K#^>+ 'YTK3\++D&JZO1O\@4O9C
MZ_)%DRHU%"K@D>3Q.C \5H0.XPE4-[^#0@&]GE,=0%+'ZX:.3T3S&XI\]'J=
M87-H8_#XAT>*P2.+Q7IFT4MN:IKXH*T6JV\>E9IFO3ABF\CDH8:)[</]/-@L
M%BLLQ>"1%5 R3XVAN/LQ+I1GX./DLWC+!ZD.<[8K^SH*]5KT3XRH>HVA A[K
M^CO$=])DEUEWDQRTC<KXE/4V8V1F0J3<LT)7-I=3I!W%UN<+4"BSSB-%+*Q+
M.HW+E9DBBEH-A1)X),AB=PQ@9+P<^H$+ OX1!%0_[?IYE.M>16/'I\KON*R,
M;Y6R+H1'[5<&CW]XI!@\LEBL9Y;3X\: <AY(T94*2"@3/"Y1#L8?W?D)Y\O2
MT6,U\V"S6*RP%(-'EM]$0,DSZ\6,RX%1VZ0 @$5ZG>@FM^'.3SX#CM10AH#F
MY8I,#$Z.JMY9+E3 (W6T_B[S*E;&'I0*'@D6;<^*1I.Y5Q3?G@6#QU#6W!J0
MUER!%<JS1/-3UO/TLO)9[\8?QH\EJ2*E6XTHN5 "CW-R>R8Q-E6+;M,5U+2\
MCQ+-2WZI^UBB62R^7S]P432<<7DF!'!B\,C@D<$CB\6:U]ZM^)M=(R91]YT:
MT\D^=U ]]/B& M6#'5@L%HO!(ROL14U#**VAV6) 5FN-Z#Y+&_.:FT=]4M-Q
MSNCA/)1_$P6=&M%0AL '@\>G%W4*IAJ9,@MPT^*Q,NX@#A?<%F^%.<TZ]$78
MB.XS-1+Z5_(9J?.":D:^?6,?CA4FB4@&->9Z*(+'V5DWG&XKQJ<:83#'0]/Y
ME9\:SCPOX&-MZUJT&0YC9*(47N6WS2)TUPD&CPP>62R6[T5!"/3".[HZ1]2
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M6 P>V=@8/+(%^ .UXL8!D2ZY[V$\+E9D"#A%C6-JC.VB&RY%QWEG@Z-D<TB
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M7WUD*[);+LH#]4 XQ#>>Q>"1Q> QC<'C_P$  /__[)WW?USEE<;W;]J0A6R
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M[\;_CB7Z;RY_84S1WS(SKF;^UE73XXN>A9Z)KN=0,+HM^@*#UT/I(3B7&8.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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MT<%71F_C?%\AB%SHJ[,/(A\I,&X:;-PYS/C*2/CF>/CGJ?"S.21!)'L)%*R
MXM4P=,WQ&O;VL3)>\U6VUJA89XQ8;XSR-7H#C*\VIFPR9FV-069M7?SUUC;
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M=%7UM<8-.*"H5'"J6N<14:C5,EAPEE9;J[B>K?CJT&J=QU+;.A2U:D5;(2%
MF$>!,$\R22;(Q) 0A@ A(0%"")"!3&2\9__>V?^34'S/USJ !MB_M?;*4NZ]
MT<6]Y_Z_L[_];? YAB.8^'SAS22AVV2/RT=[M!TB'#, *ZOOL,15F%_MHN"*
ML= M&GK.@/OG"H\L]'@[11B_04C:"5FE4%*#81B&81C&$<$1+3X6Y G/QGB<
M/SS$Z4,\3HHT\6'5?*I%.+3TZ[@(.#Y":.77B1$>/:8(KR3 )YL@L0#R*^U"
M91B&81B&B8]FS[Q<^-UBCW:^\#AED+@#GAUZK9IE]1=787Y=/EJX>Y;PDB]
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M*@@U"A#MEJS>HY:M8%G<\'5JU_+X^PK/=43>3!;>2 XVO/\E*=A+\E0,/+0
M>DP1+AJINT@\6FFB5KA'6'_/1(C5YTJ%ZFW3@X2V\-7!OIO->P/+H(8O6!?$
M,)J?Z% !T=#@[1<;-=4>514-E.]M8&]Q/25[ZBDJK*-D=QVE1?64E=136=Y
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M?SW'V:->N&\M#W99Z3H2-YV]E!^=%.>$QS4M8PX0'@=7?#0)D XM8KGVV$"
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MVQ2$>)4A4Z='<7Z=(#Z"=!@N_880:5/J:C6A3SF\+0>?O!IN<O(AUJ^N<L6
M[F[B^.SX+1W9:37J E)04.2C_:%I;8?6A:AQI14B6B>BAC6]0JY#T0J41Z9<
MZ3G#RS&5-^3-ZA1OSFEB<"09.,";]=UQP'::8O &WI(W5+^'T!2#84T $Q.(
MQ5[ %^[ '&?@[3,,TTYQLG$"&'V$R ;#TWL9)QH,3^UD>'0'PT.\2;Y_JX9[
MMFBXVU;#79LUW&E#=^XUW+;)@%MYW49_MC'@=OYOMS?^&WW-W?R_[^/?]P#_
M_D?XSWK"3D.O71H&\L=XQ@%X_J!\W G'&5[GS^,M_GS>/P?,=0$6>$ \UQ6^
MP&I_7)R:A$),9S9&,&R)EI.3W?& 0P)P. DXQH_#"9T\+J=3_[@<^7%T2I.D
MQCU3KI<1H=&5RO4NS4@]*&LDAI5U<A+EDLZ;W#"&A>Z2A$P[2?H0AN'\N _8
MP_"8'<-=M@P]K)@0JG>V #I9*))@JKK5!GABIR0@--USS;RXOJ=HB()9_VYA
M%Z<>B5%5<#E6@*T_IV'A&U$8^["Q5JV<,?1&=[SZN"_>&1&"-?/BQ60E/4F/
M"DYX:O3:%4V@2:-"/V_>Q B3DX_F]5J_ &Q:G8JDZ$KHJPV"/"DS"@4%13[:
M#31V<66JJD%J,ZA))2V$2P:#0SS#^E"YPC3GG(8/SLIIP;MG<:'><0+^?@:\
M<0?>= 2FGP9>.P5,/@G>U .O' /&\ 9_U!%@Y"%@!&^TANT'!N\%^N^1.H2>
MNX!'[8"'MDM-PMVVP!V;97-V\R8F- K76VN\&*ZSDM6CL:Z]4!IZ6%_\>_H:
M^OH;>-W$?\8MO&ZS8?SG,DYD@/NWR<>CQWV"$YU>_'GTX\]G(']>3W-B\NQ^
M24[H.;]\F$@*,/:H?#WCCW'"Q G+E)/RM=)KGL%?^TQ'>2S>=I+'I?EQ:E[O
M\?J0'\^/SVOXQH/A!TYLR/GHM(XAOD0VH$:[\]A(0$A_0RMP1'0<4QB.)#'L
MX^>7IB&TWO:9&W\M)QF&<&)V]Q:&[I9,:$*44Y;IBG0WMVVFZY F<)+$DXZ(
MIE<&U6PHF//O%OX9UM# 4%;< +<3A5B[)!D?C0W#Y-[^1A)P.Z-W)V>Q:C7_
MM0C8_#,53@?R$154(03EI#$AK8DYD@\Z1NN7)2/<KTSH9*HK#6*"I*"@H,A'
MNT#3Q(/6=.B..PG!J?FE_7-J2I=YR[OC?7<VX!9K@UC3H4:_NR7^M+IMX&5Y
ML;IN^,^ZJEEUL;A8G?^M.JV_A++XM_JO7\_^XS&Z_-MS:/[<NOY)-7]]W9I>
M\P;\U^/2O'KPIO,F3J9NWVC 4SL,&'50P[N.#&N#F=":U)K Y*1)&]+0N)Y5
MURB4I_,>P G)GC@YF2("\KB=)@@<$9#.%HI\F*KD]<K$-44$=D^\7%TD F),
M JJ@T.*_6_@O%[ICGY=5B]T;,O'>BR'HU]55V,OV[F0<XM&[TWE,&^@/RQ7)
MB PL0V%>':HJ9*/.C# J:"WR,>DI?_R\,!$^YXN1F:(7>ID&]8&@H*#(ASF
M-9$+ PFC&6**(83>Y].96/TYFBS7A XF OMYV<<!VV( JP@('<9<%X:I)V@-
M2L-]MF3;2KD13-FV&J&(Y'2SX$2.']-[^;'M;T_.1R2.E\)C?4/+W>6B5;N4
M<@@]R_X$AE\X 9KGRC##41(1FO"\> CHN1-B@G35!DE(U#J6\8I(\(N'I/Z)
MSC]II6CU44'!'$%-.S7-(5ZE.&:7@^_FQ(F&VEC-^> >;AC]H#=>'^"/9>]%
MX\CV;*0G5W/BT2"T&E?*.VKYAV)%60,G3C789YV).6/"6I1\T!H9N5Z=/92/
M^(C*1K&\FGPH*"CR8293#2D$9\)6EE9LOO-C6.C!A-YB)JU)G9'K0F\X-JY*
MG0#&'X=H-H?L Y[<*=>@:'7IJD;BT4DUBU=^QWN]U%00F;MYHX:'MFKH9V\0
M&1W'DIDX9RW6*&A2+)]>SA!5*.V,3Z40$9'ZG1W1I'>!T,0\O$/#-5:<A&Y0
MZUC&O1Z 7KL8II\B=S<FC [(.EE!P1Q!^10!KL78^E,JOIH1B9E# _'\G5Y&
M:\Y?N$O:TG[W42SL+3+@[U*,HGP9RM?0<.7DH[RT7HB]8T+*8?M#JGBLEB0?
M9.V[[+U8'-J:A6!.X#)T>K%&IJ"@H,A'FP=-/*B)+:N50O%E/@PC#FAXDC<Y
MMV_^SQ6G/UUW4G>X35JTVG331A+3&S#3T2!(8E4KV+LWV?8VF1 0*=&38U:M
MM!Q>X:MAT-X&7+_1@*LY 5'K6,9=OR(M4F_^WJ0)&&F _'+4A[*">:*RK$%,
M(SZ;%(ZA-[AAT#72R<E8S?DKC\KF_."6;)&'D9YLW.:\,+<6L6'E\#A=@-\6
M)0K[VY8D'V,>\A7"_!V_IXLPQN28*B'<5U!04.2CU2&:15Y%>AF2YY$%X4AU
M0D=W3AD<$AAVQS'8Q1#Q *:<T(3;TSU;&&\@5</7=AR/&/K8,XPYHN%;'TVL
MW=2T@6!;)@@L4-,@PQ</)))3F0'OG-7PIJ-T!R,1?K_=3%Q3-!V[VE*25W5>
M_VJ1J0)P'S^._>PIRX8)%S0%!7,!Z2RH:2=G*VJ8URY.PEO# C'P:E?TZ^IB
M'$O=QIKXI!]^G)\(MY.%T,55B]3R!B--BTDKDAA5*8(0UW^;C,^G1H@UJ)8D
M'R_=YXUYDR)@]9U.9)500"*)SA44%!3Y:'7BH36&V5'PW>$DAI5^&N:[20O5
M-WAC^/I)Q@D'PZ03$.G6Y.A$C2X1#Q)'JX:O;10Y;HT_!GSMH0FB2.GK=88V
M<HVQBVM9L<72 >UHLLQJV9< _!9"SEW2(>M^WCC?O$D*]=5YO9P)&' #?V_>
MNP7XU)6)$$X%!7,!-?]Q814XM2=7.#5]-CD<KS[FB[Y72>)QY2+S?[6BI2#!
MJ,!RE!36R>1R S/:YYZ_:PDL>>/_WDNAF-C+'\_=YMFBY./%N[TP>W0H?ER0
M@$-;LQ'F6X;*\@9UD2DH*/+1.G>B+V1R&&2#6E,/>&=1$KB&EP]I>-).YEMT
M7:^A\SJUEV\.U6<W\+&S##4DIZO4<MGPMU5HS3)AP@L@K)A?XR2W[RY-W+DG
M^]@NC2YB%U;XU#3D+Y$0LFFFG!CE[:]@+J"U)V^G(JQ;FHSW1H9@PI-^>/86
M#Z,UY)1B+H+XNKB*Q'$*X<M)KS7)31>G@_GX:F8T!O1P1[_N;L*AJR7)QX@[
M//'.B&!\^V$,=JU/1X!;"2I*Z]5%IJ"@R$?+-7IUC8G5V55 2#X3 75RK0JP
MYPWK2C^&-TXS]+9GN)<W?S=::^A"PO!U2AQN#D6Y(E][0H0W1A7*A/BV;.G>
MY*)&UV4:)TIG^//^/5C#(I%2+S-.* >%<E*>W 7<NQ6X<9,D(^I\7QKY(!,(
M>G\KVUV%-G]3C#'1L.NK-9P_4H"5'\=B4B\_C+S7"T.N<S=:0S[T!@],Z.F/
M]T>&XJ<%B3A_N$ DF!O]=R[_I4NK3@MG1''BP<E.5U?T[NS2HN3C^3L]A37Q
MRKEQV&N=*70MY+ZEH*"@R$>+@!Q7*?ROF#<A07D,VV,8%KC+H#\B')..4VB?
M;/)(1'Z]-6]>R JU42S^?VKRT>:+DM97^0.!>4!F)5!6:[R$<],T&Q<G<&1F
M0,&% ;E,K&2=3I$K@&37O) 3JBD46KB/X?ZM,A]%G>__790;0\YSVZ(EN2O4
MRYL/"@IM]O. ?R"0S>W)W;E8^$8DAM_N@2'7NZ%_-^--#$;>ZXW/)D7 >F6*
M"!,D'01E>AB;2-%K(;W'@FF1<F6LBW%7QBYM[<H;'[P<BN^_2,#^S5D(]5%K
M5PH*BGR8?-K!9.HXK_(Z(+<:T/$FY$@RPWQ.//KOUG"7K4SO5N)>\Z\1!X'?
M0V3Z>$6]#/XSQW6;"^M8#5(?0IJ0)=XD3 <&[*&4^<802LN+X9)J,O?'Y&/"
M<6!#&!!1"*172,>Q]G27O*EAI3U]<RW2W,F2#6O3Z^IHH/"[&KTF O[V;<S$
MAZ-"T*O3>5[.(@S06 WY^"?\Q,3#^VPQLE)K&H/WF-&O33JWI_?FBM1T"C'L
M;>37<4GDXQYOS!D;AE^_2<*1'=D(]R\S.M%24%!0Y./"'20J6K6(*6)PSH!P
M&-H> UCP1N1+#V#<488'MY$S#CD+*4U'>Z@7#LGS2U,/?>.*C3DV,1="+?GS
MS^*OQ3<'PC9X72BPU ?XX!SER# \S\E6;WN(:0@Y/"D"\J]%$Z(Q1X ? @&/
M3 @G.TJA-W<T)5[7Z&6 &^4RY&?5FG45YM:AI*!>-,*5Y0;HJPVB(388)"EI
M[Z!SFI&LAY]SL;A#_^V'L9C2Q]^HQ(.F#E23>OEC[9)D(;XN+J@3[D\& S/J
M[U\Z9PT-1#[R\,74B&;$HV7)QZ@'O#'_]4C8_I@*YV,%2(BL%*)Z!04%13Y,
M0C[H]Q6M6I"CT I?A@_/,TP[#8SBS<B@O>2,Q(0C3O?&N\=*R&O^18&.UA%
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M;9C:EV^'H7*T,D>--Q%+VRAI9]L>T301(?U2'"<C^Q,8EOLPO'F:+'J!6VR
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MKW?#JX_[8M8+P5@U-QY'MN<(5SA:MZK5:V;E@*:@H- &R =]/I*0MH8$YI7
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M%B;BR$\G$!F4C[R<TFKQ/-E;Y8,"*NQA''"WEZPK^S&L#3YZW^B.^:]$PO7
M261E%N-,7BE*C8W2,,,,,\#'A48M^Z)",S*/%^'[E2EX\1$%/FH[X?8;?="B
M?0BNZQ>/1B^=0.TY9PVP40[/O589X&#6M]XJ,QJL5K[*=-Y7,QML4FY&7?4S
MM5>:U+\Q*0!B%@!B+]^US7? ; ^]ZD$)5<Z(,&O&"U9=@0>E42D5&^*3*_+9
M!!E+9L7B_?$1F#$R%&\\$X+IPT)%/I;#T!B<=;K*&>T:...>>LZX]18_W/!(
M#!J/RT2]&;E2_:RH[^O>;X%G]^M#"W?%:(C(MO^'P_5 %MX?%R%4J':U'*T>
MN%HRYS-'A6'GAN,(5O>.M#B*@52'9\K>>CXXLVK1E"@\<J.; AY. B"M?8V]
M;W*7?@]6K K4?>.02K.!/0PSS# #?%QXH!07:<C/-2$EH1";ER9+R?]>=="V
MOMH=M]WDBQ;M0G#-L!34?>=,-:PZD&NN>ZTROW)E.:[^O/;*JO<Z"G345^#B
MJC5F-%YCPO_6EJ+INE)<^SMO*F["-<K_I[S1&@(2DP(J)M1=I5GENG[O5UYL
M3<K<LFZU5IY?2ZXKJS(6YUIWV )\Y*=7/0R[O*!"ITRI_YKTY &=V54."J4S
MX"'5(S7QK Q7^_SM.%'?&=[9%SV;N:)C?2>TH^1H!<'TG==YHD7'4#0=F(A&
MXT_(^U]1WU?/'< <3\ Q&0C+ DZ<M>=UUGMB7/=GX=WGPT4^U58!-A6UYDV*
M$GG8M.0B!2!+U/TT5XMG[[S:55:U5[OB/70_I,#C2^&X_ZJRJ>96GDQ/,8+'
M6GI(M274-]?8L RSZW.&9XSE?#E_QIP_9_Z:FR_X76:3_OOY.9J1Q+RL]]C\
MA_O\1S>;S@^XU?["S:H0?/ 74HDC+OP,W'F@J"#EV?O]<&]-1]S=P!5W7N.!
M5K<'X-H!2:CW5GZU !T,E"7H5X%[TW4:;MZHX:[-&CJJX/C!'S3TV:WA\1^!
M)W\"!NX%GMX'#%7^S'Z("L^H@\"80\H/ZO[<H;_O8W\%GO]5PXN_F?&2\O'*
M7SY,-_W.U?\?,6."^N]XY>/4S[SPJUG^W=A#VC_Z?(M;OLMHY:/4=QQY@%EH
M7?*4,Q>X!H-^!@;LU=?E">5]]P"]=P&]=@+=M@/MO@=:?P.TW 0T^Q*X>JV&
MAJLUD=CE6G?;!GSJIR'! !\VWR0LU4F*0J2G%,K[RHH&LZMNA[*E8?RW72=P
M8%L&]GV?(0H_%(]@)?/CZ3&8,BA8O=>^Z'NK![I>[8SV=1S1MI9#A9G\NQJY
MX=96?KBIDP(@@Y+0X+53J/G9Q<%'G]WJ^? '0DY")M_GVJD8 =>:=#4F9'[=
M>0)OC0I#Q[JVFVK.X/7#UZ*%(L<>"ZH0\IJJPW-(,$0%,-+U%JEKI'2MK=:%
MSVIEYGQ8IIH7Y)?BR(^9>&=L&.YOZ'AN5HBUKHU5%597.'AQQ>PX:78WS#![
M.V>8N*("8G+\680H .WM> JN![/@L/>DT'4/_I")_5MYSJ1?TEEQ_T7]+/<+
M*JD>^?$$G/=EP>O(*;6/G$;DT3R1PV:"Y>\$MX;]@WM\JD3F6(7[YXHBG[=#
MMHHELN"F[C4IHZSZ>_R6#1]U_P/<<H2ZG9E:A,("DPXD39>^3U=<ZJ!E R&!
MQ[8U*7COA7 ,O,=+,J*D7MU=SP5WW."-Z_O&H_Z;N=4"?-0NF[3=9(T)=WQE
MQ@/;S"JHUE1 #[SAHF&ACX9/5)"\+%##FB!@0Z@^;7E+%/!#-+ G#M@;K_O/
M_]#W)0"_)"I/T+ _4<,!Y0?+\0.)9OD[.G^./[]/_)]?@\7WJN_UD_(]L90Y
M!;9'Z\WAWT0 &\. ]2' :K4>RX\"2P* Q7[ 7"]@EALPQ5$'+@0F#V[7T.9;
M#2T5J+M^/0<+:FJMS>CU@QE+ S0DYAJ;@ZTW# (/*N9D'B\6*L[A/2>P;6T*
MOO@P$9_.C,'<B9%X>VRXJ/I,&10BDYS9-S#^L4#)%C]YIQ<>OL%-&FX[U'42
MN=$VEQB6=T\=9ZE^WJ[>_^;=(X5^59'H!)\=/F/I9X#31?K<$'LTKC4/P_24
M(OSX31K>4&O:L:[M*A_]6GGBTS=CI4>'((A90W,UX#?R&BCYRP-JZYI4S!X7
M*70]6P$/GDDCN_I=$GSP8.6[<C*C2(*>F2-#T;F!DU6K'GR?2,VC1/*(KK[2
MKQ,5E&]L7H;9C?']9K6<R0X.$Z52VP]?I(H*XJ<S8_'!I$@9M/KFB%"\/B0$
M4P>'X+5!0>)3!AX]Y^?^;% PICX=@M>'AF#:\!#,&A,F0@P+7XW"RO?C9?8.
M$V0^3J=P+*X )2J@-:H@UK['.'>/2><EX-B]\3@V?9*$U1_$8\FL&%%8_.3-
M&)$G9W5[K;K_K#8?V)8NU=R<K&(4G=4!R*6 8H7@@^7\</\\F<+ZJ?K 5_H'
MJ<//XT\9T.:]HM'PM1RA70CO>UG54:<LE"FA,:T"ZBJOMUJY^F_]U1QN=Z%S
M^G+S]2;<ML&$GMM-&/&+&3-<-2SQU[ U2H-CL@:O-.!H)A"9#14L0R9Q<R9%
M?HD>%/$L_S<]XY:9#:4F?:+TV1(]\\RF<'[W)+4&L3E >)9:EQ. ;P;@>APX
MF*2 2@RP28&3Q;[ -"<-HP]HZ+?;C,Y;S+CK:Q-NWVA"R_6EZ/=#*9;[F!"3
M81+T^T<O4H%2H;A) CB+\V&W. ,#/G/EE6+/EV%Q;A.RITR(A:KS1VK4^9*U
MA1)E/D>+HG.-N&:%EO7[P[IRHR#7GH/*HH+SA4;UY>)$S)D0@<D#@_"L"G;Z
MW>Z)GBKPZ53?24!%5<VBN+?,;[DS$$V>246M125E[_^?>S]872/8M4PTM]?W
MZTR>.GS56K/1^_N5R0K$!=FD5\ 29#]^FZ=4H*M;YIS/=$QHO@@5K)Z7@&G#
M0O%D:R\;K(E.#^34=]*\OOF\8O!16&#&R?0B)$2?P<X-J9BF@A^^%]:\1@XN
MI$I9GY;N,A-F_:($.:C+VR?_52Y!R*7!L65OY'[(_:^\?<[P\IUG1%57/G]/
MJ>)9Q#.(YPR5V2A0$NJ7AQU?'L?\R5&8\/A1=<;XX?$[/(6RV_5J%ZF<\WVD
M;'6;&H?_[#7U][4MAZ76=41'!?Z[-]7?#R:W7^P=*&#DL[=BL7O3<1SU/(W3
MITI$G(%]4KP>/B>\/LN96IWV03[S$M^<U=W:SP _P_(<5!:@_?X>\]_R7>79
M1M$0)C')G-BUX3@63XV6\1H3^@5B5'=?#._LK=P'PSKY8$P/?TQ\XJCTAZY\
M/PZ_[<K$L=@SR,XL$G5<OL=RGRY2!:D0?/"BJ BRZ=,DS%"(=F0W7\F0_GYC
MO;N!"VYN&X*F0Y+18&H.ZKQ7H"O?_.-&;8@"%.D]I$ZQH9GTG]Z[F475A"Y$
M^A K&B_^IOLXY2\?UC#%0<-T1S/F>YFQZJBF@AY6% "/XYH*L#4)M!EP'\\'
M3A0 .44*>!3KTK"E98'1OPUA2]!;-JU: (CZKIS#P>].$,*,=&J^OB[QRJ-.
M <$G=2#BE*)))>C;"%9'-'SLIV&VAX9IATT8OZ<8(S878/S&7"S8E(5OOTH7
ML/KCUVGB/WVC?',:?OXN#?NWIDMPPJF^+-.Z[,^23"G+K,QPL+S'C8;EW(C
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M@E01$%":%,6"HJ* "((H*(BBV! [=K%7A/1>2>^5D)!0$D(@ 1)@_\]OWSS
M_U(G";F7E'?6.FO-FAGRWKOWG+WWM_>WOWUC$T]I>9*7M#O36[J<[Z.[B52N
MLMW[I7#K/LE.*Y75RW-D<N\-<J/Y![6]FQ_O):U/]9;V9_O(P.N"Y.';8^25
M.6GRP^K-$A>V4W;MK!#WJKLK.[5,5BW.DCO:A$FK4[SEIA.]I-EQGK:<%?>N
M?WM8NW!9^'BZ_/A+H41&[Y:\_'URX$#].^?[*PY*6>D!V;ECOWA^OTV>NCM1
M.O[#UX%GZ*&[^X5^LO"^9 G\O5!VE^R7O7L.R(']!VW_W=O,^XH)*99?ORR0
M+U9NDO>69LFK<]/DL9&Q,K1YB+'?GH[==SZG>5-/:7&"I_2^U%\>&1XK[RW)
M%N\?MTE*[*XJ^XH(OQWRW+04Z7:AOS0S?^]&![Y_U_/]Y-D'DB7<=X>CYS8M
M?K>L>2=/GIJ4*.-[1$J_JX+,\_.R];>V/]-'QG>/E.>GI\C7[^;J\]Z6O[?>
MW//4N%VR=DV!O+DP0QX9$2,#K@DZ= ^=..<]+PF023=OT//RQ5NYLB&P6..Q
MJJR*\H/Z_]U95"X^/V^3EV>GR;AN$3+(Q%9=SJL]>]7J9&_]GK<U"Y'[!T:;
MF"U#?OVB0&)-S):7O4?VE.X_JO=07%@N&8F[)<R[2..+>_INT/BBUN[J<>9=
M-O60;A?YRC,/)$G@^D(I-<]MW]X#LK\&=I5_LZ=LO]J@$,]"8U^2I=>__&T_
M-\V.L^(MXNBVI_M(Y_/\I/M%_M+A;%]]1RU/\C:V,D!&&C]\_Z!HF3,Q09;-
M3)-WEF3)5ZMR9>U76V3=UUODFW?SY(,7-\KBAU/T['7[I[_MY[R=L1,]S3,:
M=$.PV4&'P0<O?V-ZJ40%[S"7,-,<X$C['(IY< 2M./-;_Q,HH]N'RM-3$N27
MS_)E>\$^=X1?AU=62JFL?#9+ Q$<N1MXN/>1^^Y>&^3]Y3F2D5$FA<8AEI4=
MD(,'Z]\YQRD5%U5(0>X^^>7S+3)K;*(:>"? 1S/C*'L8)[EHFA6\$B#A[)QX
MCNF)N^2'CS?+HNG),MT$8N-[F$#F^B#C6/VD_5D^CMYW/@O@T?(D3QEBG-6+
MCZ=*J%>A B2</L^E*HMG^-R#*=+U G_'OC_@@\]T&GS$1Y3(.\]GRT034 RX
M)EA_<XOC[04?^/&';HN1#U_:**'>A9*97"J[BNM'$K%\WP'Q_76;+)F1(B,[
MA$J_JP.EPS]\'+69M]T8(HL>2A&/[[9*<LPNV;IYGP$55<O8$  3N^5OVB/?
M?9 GCX^.-:##QP!";\TTUUK@>(:/##'?\[X!T?+"HZGRP^I\ ]IV2\F."@4>
M^X\R,<)[V%U2(47;L+<%,F-TG+0^K1)\U!H \31!MI\\?4^2^/ZR77845B@
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M$\SCJ*#K4/5P1"F)C%/3]=+BQ/72_FPOZ7ZQC_2YPN]/=V_=_H?WY?[2Y_(
MZ7-9@,HMDI$^<O<R[PD0!:66^XOSXG<!J@X##\]C4_70GB$/Z76IG\R=G""_
M&7]$]6EKOL6#KZ[P"$[XS6<R%'C 5T>IRV[5)X*U1PRP(W!*C=^M@9H3]$.
M/B"'[.7/G^;+S+OB;>]O(="B&;B3"2YN:Q$LK\Y-U^I;G:92;MHC4<'%>K8
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MSK4ZV5-9/B1O$'>@&L;=LYT!L]^BG)&,QF;GY^Q5-@Q5:^)KJ&C0M& <54=
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M0V)DV1.I>M?I9VH0X*/5*0P,LIP*+[QA9.B\U.!P0 B>F&@)"/GPI8W*40>
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M&3>Z^>\-?A-$ 3A&&\#QP*!HF3LI45Z>E:;#VJ("=^C4TH:XX.@SP34]D=D
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M@.1MW"/QD27RS?N;-3CH>8G]\XB0FB7[/K)=J(H4.#UUF.9Z*%=W&+\"-8,
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MMGQ>8ORDR*%#(HW@<G_1]E76&E^\3Q(B=LNG;^PP/BY1^IP;:.M>Y5[V_%.
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M.$><1_,*,J@&<.V @&H#A@$$@)"JO35:Z2$;B$,&/) 9 HQLS]DGV[*J)->
M,(#)UDS^>Y^"#"AD5&WRM^W7 Z:DT*I [*ZH/@IT'%;@[0$>'J?K@H\3PZ@R
M47$J*3RH&<ZE]Z6;P"/84? Q\Y9$V;BF2/<>P1?[VK5C#%@-: OW*5>JI!/@
M$9I+5ZK1YP88GYNBU$DG#3].Q7;>A&2E0E]_<;!T.MW7=L %]?>9AS)E\_H2
M$XSMT>IW8QGO(4D@OTT[Y>VGMRD]=N"E(8Y1(#E/K_UKD(PV]W/FK?'F&K9*
MI'^%16.NLBK2367/$Q!SOZC4S[T-\.%K*_6[C]GG2^Y)DU#O<DV.X*-:0G6>
M\W^G <.P.;R^+-%[X$1RH_.9OM+[O  9<%F()OQY)UHL^."+<S@2P$7X52B7
M?<Q5D2X(: ( A#+QE6:SPOGEX!UH-NS@?X7(S6U"]&":9$#)/</BY2WC3*.#
M*[2$Z,G@-[<LIV<! CQ<3)QQC8(1*P,*(,$Y<V# C691JJ[<4Z._>GZ/M;_J
MD#I3?@:PP<__)]B0H^AK;L7C1#.>.<"#P^6;=<7:,T0 XM3[V_%47^U+VK*^
M6/<>>YG]YEK]C'L&\*#""_7IL:EICH!'_&WOO_C+#9<$R1/3TR1D<YFCWSLK
MI4K>7+Y5QO:*-$%*H'0YRU^I@G;W)]T]*$[>>SY/::4D=\C -Y8!9 BRH#K-
M&ID@H[I$:-7#*0HDGS&\0YC,&Y^DP(-^1FC$G >':IO.>^EA 0  _#:5:H\C
M ,W.>]/[+P&:V/3_9J=4E%?KF<DUG.C&]R1Q&>I3+A^]NET>&I<L_1SP+]W_
MZ"^#_ADJ8WM&R?/SLY0&WF+!AY4EM! W2! ^/0V\!+QD@,A,N&"@"36JM[+6
ME;\WA^3Y!I3\;XC,FY@LZ][(EV1Z$N+V*#U)>Q#2JNKZ#_8IA8EG[ ;9KK4$
M(VL.\("J2%#UP"V)<O5Y@?8G#5I;P=R5O_.3^1-3-.ARK0'!066M5C*C@RJT
MCXO^B[X7V@\>>Y[CK[TEXWI&R,I%6=H?YJ11(7AI4;92H#N<9H)S@(?-C=CL
M5P1/Z,4H*3BHO7^_EHIT-&V.Q";-\P^-2U0:6;^+@ASI\^![437J=K:_3.D?
MHZ(%O(_T[)45'VR2^Y[S&1 2]%VI"J5 N:,R9%>?$_U$#]R2H %X?/@NR<NN
MTF3>B6Y4EQ(C=\NFCXHTX3[MQCBYY@+[_0L^;&R/*)D])DG/)01I6DI,]E_!
MAU)># "!XL++";5G\G71<G.;,,U0N$%_TU/*Z@@]P#C57@8DCND>I<C]A?G9
MVEB[TAQ>9)G>>6:;?&R<RL8UA7J(0T%JK&9UUUQKRD8U%VK%VE4[E'(UX>IH
MVQMWE6YUJH]T,0$#6>M'IZ9*X'=E[L-H@$&)(3CX>JT)#A9F:V:>+*W=SZ_?
MWX+,7HF2AR<DJ>^DW\1)HP'ZQ4>RY,9_A:KX"Y0HNU6@$$= +?";CXLT!J"R
M7/LKL]_\/-5H%)P(L%Y?EJOTX7X7!>I[""W1[F?9Y7=^FG! :((&=QKI$2\H
MS-NOR8FF"CY8P=^7RJ-34K1/I8.-(D!45F[M'*[ <-6R'(W_$)LYT6U76;56
M'8B1YD],EG$&$*"Z9O>>9"_.&)&H"0:$<#*3*EN,3S_II[(4!*5D.VB^6;\Z
M7_L+[KHAUI%2E+L:GF'M>)JO2O9>^U=++8O-?=._PV18^W -N.X?&B^/34W1
M9YJ>L$=J:@XUN[X0UUP[5J,WZ/M/BV7%[ R9.C!.$RD$(_9S>OVDQY\#I/^E
MP;)L1KJ$>)6[#Z,!!N4J:'.9K"8X,($C"1;\G-W/CWTR:U2BO/9XCO+NJ1X[
M&7BB'/CB@BREV&HC=BMG^I,>JE/VJFDDZBY461( 5-X):)\R\<30MJ'2^0R?
MNCX/^[\7P22RNN/[1,D+YIX&F8 >T $5M[:)4XM0>EQ\=XI2 #NA0GJR?=4A
MP&#_OP?)I&NCE)8&0#O1C<J7EWF_5\S*4$4YFLU1'K5[3]YR180\?F^:?/6!
M);]>L&U_RP8?1V<KMF5:5 7D2IF+0/\'3A^$3(;$#?R;.BCQ^:'<W.>\0'6^
MMQOG^]3,=*V D$U,BMIMR<::@P[97/BO-&E#NZ/D"N>4O> "%->:JR%(0*:3
MN2_#.X9KOX?=C;N>@&<@M!WSSJU\+%ME=ET[=F,FRK>?%"N FVR"@\&7ARF5
MS>[G-[I;I";>F'$4$URA\N9.@ Y/GUMR]&YE'MQP:8@ER]G*YKY" P*HHJ-T
MY;=Q9R-\%RN1204%^J__UZ4:T#XP(E[Z7AB@?8RV2IG6R9FRN(=3!L3(TOO2
M=/:27?+!=AC2MZ\8_S&V1X2*S@ 0[-@+'G&;CJ=Z*P!!^2K8@'Y$7JA<-160
M1ER"X P]8 3L**?M4<& 0PT2#&!NVE?O%6@?T+#V87H^V*<L=F3=UC-*7GXT
M1^F<)#:@P[O@0RS5(4_S.92%=Y_;I@/=.+RI@-@M^>>NQCM0 (I=S_)7-0N4
M12;UC9:';T]6R5%43="0I[R/:A9S7IB'P6R-K09\[JIK/*NM<=&':\W3MF7N
MDP]>S#/!1ZQ<9WQ7=X>H'OW_'BP3S+NVX(YD[55 2="U8S>2(=R_^TW0>N/E
MH:H0T_$T^Y_?'?UBY:WE6S5! X"%_F6W::.Q":"8!900ODL'GC)WPVZZE6>>
MR15G^LC#$Y-_=7_2D=D)AZ4@;[]64EY<D*W5]Q$FAKCJ?_Q_H W;/:>%60KC
M3*!'Y9.!KPPV;$Y#/@E, <#/SLW4^T=FWBY)8JI0 )!K+@C4WBH2S\C5L_\!
M(,?;V%?X\\!O2V7M:]OE^T^+)-RW7,$M%+&&4.CXN77F[YIV8ZQ<>V&@V9M^
M*A)BNW^Y+D;>,W$U,3;)7GK;7/!1EX%1F5.#)D&6Z'W3/W#OD'@M%_7ZL]O_
MT3P B,435EK6J3Z*Z*E>77-^H$HWDN'H_X] <Z@'R[A>D?I\D7W[V+R,](:0
M[0. N-*@KC578Q8.D^='=HV4+F?Y:=7#[N&IO'?0'4G8 .J]ORK13)UKQV[<
M-U2?1G8+E\Z_]Y6.ISLS_);!;AO>+]2&5 0ZG)!A)>E'8W;EWAJ=543 #(AU
M8N9 ^].\Y<JS?63^Y"3Q^_K7@P^ !_3MS.1*E=6=U#=&A^B2N+1;M<L#J  >
M[4[QEON&Q<OZMPM4;0L0>?! \TFF03M,B=TKOIM*Y:6%V7H?[4R>$"]07;EK
M0*R\8  C<T:07*8"<KR!!RO&Q"6K5VR5F;<F:/(4$ (88<@Q?47':BBZO?OL
M-AG;/4*N.)UDK;<C5$!ZUQ!UHC*H#)/:EI/@/:F^?Q!G"#6'C#B;$46$H>9@
M[?Z' -6>=L*1N,NN[)"7M&F]Q1SHWM+G_  9_.]0F600.0"$*HC7%\7*CV7P
M$-._V0>>87U*S\*9E]<U)M:ZU1'7FIZA]O;*XASU6>U/M:B(MF>2#?@8VSU2
M*8XT2D.=:$[9UJ9@GF"#J<.O+,Z6F]J&2AL33+9I;=_DX;:MCF3,:;S>K(._
MG)OY0[".3\U*V:O#[YR2A>YZMI]<>U&@#.T4)L_.R]#*]Z_]'H5Y!W0(+!3?
M17>F.CXSC KGP/\-D=$FJ'SAD6P)\REW=$)]8QD5!WP'TLMK7]OQP[1S.P4(
MZ(DCR4S/TTL+<V3#!X5Z_G,=4)P0);+; /P 'D0!J X +A@2^Z&)2QZ>D"S#
M.H3*?4/BE1X&,X<Y/,SV.I8J(S$+O4AO/IDKMUX1;CL5T,-&X0SBVC=]6-0B
M$[OU!A]0;FC:I$> QCMDZNX?%B\WM0E3N3"[]:?=93<GUDO:&[2/G#*](8.,
MPQ[?.THE21?>D2)+IJ7*DS/2Y;FYF:J<118+&@1#J#BD:$J#@PE5P#77FB3X
M>"Q'&X@5>#@P3X!#9K(!\2C[,'>'PQ-5%=?J"SR.]#YD)%7*2G/F<-Y8\N+V
M]LDA:=O^5%^9/3I1?9R3MKN\6E6UH)-PSI(==8)ET-@4P5UE-1+J5:YGQ?P)
M*:H@U.M/SK(EAK:S*H^KF>>QH43?P>9H)'_)CD/-00YVCOE.@$74]*!(V3-@
MTU=![XA.X7+/3?&R?%:&K%NU0Q.1^%.J@;97?,SW)=E)KQ!].F\]M56O@^3W
MJ*X1)O8,U#: .ZZ/D7FW)RLP2ZWGO@6 UM3)/VME?&FNC.@89CL5$,#(<^MT
MAI_,,/$55247?/S"@^(A@<#)9GR'<LR#&=K\QX'@A/*(NYR9I [7D:P*0(3#
M GG":\X/D&LO#-!A6TCQ41F9,RY9!^-P4*%#GI6\5_>'*]OK6E,S) Q?7I2C
M@@O6P$X?1]XG#NU/WLB7_+S]4EY:K9D\U^I_YGAZ!JBTKC3/[Z;+[9\Z3'!
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M+)N>)K?UCI0;+@M6GVWW.T53^Y)I:?+5^X42'5BA9X@[_,LUUUQSK3'L_P,
M /__[)UW>)35NL45%!#LGB/JL5X]>H!$0B\2.H@4J=(%J2)*D^:A"*A8$!0$
M44% I8A2!0&!9&92)CV3WGN;9-)[3]:==P_Q>KWWGON<!R?F"^OW/._?C.;;
MW[?7WN^[%O"ON G-@(KR.N3G5,.<4@E??0%^W)>.C]?$X>T%45@^*13SAIHP
MOK,O!CSH <=;='!LJ4.GFUW1Z2862QLES^R()[TP9[ )FQ9&X^37&8@-*P$A
M6B<ONPKGCF1BS<MA&-W1"P,>\D"WMGJ[KZEIO?RQ:WT"?'3Y2(@J5;^CKJZ>
M?Q!""+$SS4)\U-;4H[*B#F4EM;!D5"(^LA3!WH6X>MJ"HWM2\>FZ."R=&((Q
M#M[HW$:/9V_5P:$%-[0L[51GZS,[I8<?-ED%];$]:3!>R;.*[0J^P8CFR<VJ
M4@=&BT8'H5][-_2X4Z^>=WNOJ=D# G%H>PJ28\M0D%N-BK):U%-[$$((Q<?U
MD)5>J43(Q1\RL7-#/!:/#<'PIXP8_*@1SNT]T.<>=W1O9X!3*ST<;G95Q8TN
MJRF64RL=Y@\+PA?O)%J%1ZZZ]9 -$R%:)]M<B2.[4S%K8 "<;K,*[5:-<S@D
MZ^G'K])1F%>%FNHZU-92>1!"",7'=5*47XV4^#*$^A6I6Y##GZ5B^]HXO+TP
M"BM>"L.\H4$8Z^BCA$A#.Q8%"*LI5I?6>BP>'8S#NU(1:2I&1G(%2HIJ^ 8C
MFD=NJ^6YGND<H(3'L[?8MRVVX:!IP? @G-R?@>+"&B4\V')%""$4']=-=54]
M2HMKU3R(;-;B(DJ5$'$YDXVC>]*PPRI$WA@7@E$=O-&YM8[M6*PF6UW;Z+%\
M4AC.?I,)<VH%"O-J5*LA(5I&VIPL&57X[M-4S.@;8'O_*G&@LZOXD']CX?-!
M.'4@P_J-J%&_HYX]5X000O%A#^1T2X1(@$<!SA_-PJ?KXO'ZV!",[NB#YY\T
M8O CGNC?W@.][G)3I\ULQV(U%?&Q9GHX+I_(1DE1K3)9J*GA9HEH5W145]6A
MHJP.23%EV/]!,J;T\+?[.I);E2[6M=3C#@.6C@_%N<.9ZC<00@BA^+#K1T]Z
MY5/BRA'L(T/IMEN071L2L'5I#-;/B<22<2&8W-T/ QYPAV-+5W4:1P'"^C.K
MVVT&K)T9 9<S.3;A42UM(GR!$6TB)B%R(YT27PYOEWQL7QV'\<_ZVGT==6^G
MQ\"'/#"Z@S<V+8Q2[__*<BXD0@BA^+ S595UU]JQJI"96J%.WJ2/WO-R+LX=
M,>/ MF2LGAZ&,1V]X=1*3LM<X<AV+-:?*C[T^.>L"!C.Y_S:G\XN$:+E=W!:
MHNT&^O0A,S;.B\*H9[SMOHZ>N\\=8QU\U+#Y9QL2E&L<VQ<)(83BXT^ASKJA
MR\FL0DQH"=POY>*KK8E8-C$$XQR],::#%T8^[87ACQO1[R_NJ@6&&V)68^5[
MB.UH[[O=\/;\*'A8GTU"M([8VLJ!SX7OL[#[[02\_F((ACUFM/MZ&ORP)UX9
M&(B-\VV6U4%>A6HVD!!"",5'XXN/NGK52R_VO''A5@%R,1<_?)F.SS<GJ!.R
M3];&8\NB:,P99,+ ASPY"\)JG%F/VPSH<X\;AC_AA0^6Q<+;)8^+E6@>N7GV
M<<W'_@^3L6I:.*;V\H?S_1YV7T\O_-T+;TX.P[[WDU3+55QXJ6IA)(000O'1
MZ(C3B7B]2S^]6)C*+4A:0KGZ.,D)78B/S25KZY(8O-C)YYHC"S?'+'M:@NJ4
M\<'@1XR8T,4/.]<EP-^M@(N5:)ZB_!I</F%1!SHR7S?L<2-ZWN%F]S4UH;,O
MWGLC!I=^L"#4MTBUW=8QWX,00B@^FI8H:9@1J5%)N!)*M6IJN!J.E-[A%SOZ
M8.3?O3#H;Y[JA+I;6[T*A..,".N/L 25-A$Y%5XQ.4QE(80'%'-1$LTCIA]G
MOS%CV<10]8S+NU/<!>V]IJ;V],?NC0D(]"A :D(Y"O.JF>]!""$4'TU/?(@S
M2U5E/7(M5>JC=>J &5^^FX0]FQ*Q:WV"N@T1AZR7NOEBR*.>Z'NOFTI-YP::
M=5WS'E8!.[&+'_XY.P*'=J3 [4*NVC 1HG7$Z>K'?>E8-#((O>\QH'L[@RU<
MT,YK:N9S ?CZPV3$1Y2JWU!>6DOC!D((H?AHF@)$;$UE,%%.RC)3*Y$87::&
MT^4DVO!S#K[:FH05+X5B4E>; .G6UL --.NZA\W%E6??!\D(]"Q0KFSR_!&B
M=?*RJW'L\S2\,B@0G5M9G_5;Q-+<_N)#ALUET%S::N5&N[:6?PM""*'XT @B
M1L2B4>9#Q*M>YD'VOI.(]7,BE'.+G+!):]:8#CX8\:2M+4L<B\2YR-X)OJSF
M47(2+#=J)[_.@-DJ>*55I:*<NR72#,2'I0I'=Z?A9>< Z_O01;T3.]WD8O=4
M\WE#@U3K;%%^-6\\""&$XD-;-+1CB0"1Z_OHD!)E@WK^2*9RR3JT/46U97VX
M/!;K7HG JR\$J1F1'G<:X-!2=^UCRV+];^6B2O)EED\*5<]4OE5XE);4JE1H
M0K3[WK3ET^1F5>'(9ZF8V2_ ]BZ\V;ZS4Q(4*X&Q\X>9<&)_!HH+:OC'((00
MB@]M"A!;.U8=RJP;0SF9SC97*@>5M,1R1 ?;!,GI@V9\\E8\%HP(@O,#'G"0
MWN86O/U@_0OQ<;-5?-SJBI530W'YI$6)W&JFFI-F\<ZT92J)@8+<$-M]/=TL
M;5TZ=&ZEPX+G@]1-(L4'(810?#3+#ZQJR8HKA\E8B'.',['#*D!>&Q.":7T#
M,*6G/R9U]</83CX8_H01 ZRB1-JRNMZFAV,+BI(;W>5*Q(?TPJ^9$0;7L]E,
M-2>:1X2SO!,M&94(\2U4X8*3N_LW0E:.'L_]U1W#_\.(MV9%X.+Q+/4[""&$
M4'PT(_%AVR0VM&3)+4B8?Q'TYW.4PXLX%TG(U>>;$Y53E@RJ2^_SZ [><+[?
MO5%<7UA-N%2;B%5\M+:*CYGA</TI^U?A44_U032*W!"+6YN?(5_=/FR8&XG1
M__"V^WIZ[B_NF.#DB]=&!V'/Y@08K^0JERM"""$4'\T.V3!*<*&($&G+$J<B
MZ77.2*Y 8E09(@*+U:GVUQ\E8_W<",P9;,*(I[Q43@@WX3>R^'!!)ZOX<&KC
MBK4OAT-W+IN+B6@>"7"58#\1'N\OB\&"X4$8\HC1[NMIZ&-&O#8J&#O6QN&G
M[\SJO2OO9$(((10?-PPUU?4JM%!N1<2N5TZVO]N9BFVK8K%F1CCF6D7(]#X!
M*OE7$GE'/>V-P0\;51!7]W:V$$.FJS??ZM)&A][6O_7 ASWPSN(H>%[.XZ(A
MFD=N&XQ7\K!G<R(6CPE6MQ%R*V'O]33Z'SY8-SL"W^]-@]?5/!462^,&0@BA
M^+BAD/Y]\9B7C[$,J,>%E\+?+1^Z<SG*V>BX]2-Y<%LR/M^4B(]7QF'MS C,
M'6)2:>J#_N:!GG?J;:?C-[G8U9Z2]>=4GWO=,.(I(Z;V\<=G&^,1X%[ 14,T
M3VEQ+:Z<LF#SHBB,=_)1>4C=;[=_'I(<X(CKH!SRB"NAO'/%J9 00@C%QPU#
MPTR(#&#*+4A#6U9Q88UJS9(;D=3X<M6BX'XQ5UE2OKLX6K5EB5VO<WMW.+2X
M^AL!P@U[<ZK!#WMB:F]_K)@<AF]WIB+,OYB+AFB>HH)JG#Z4@=?'A:#7O09T
M;:>SY1[9>3U-[>F/O5N25"!LMKE*#9O3-8X00B@^R.\0,9*57HGXB%)X_I*K
MLD/$KG?3PB@UH"Y^];/Z!ZCVK)>Z^6/4,][J5D0<L[JUU5_[J%.8:+'&.?IB
MU;1P?/5^$ES.YJAD<T(T+S[RJW%B?SKF/V^"4QN=LI*6_ U[KR=Y1Q[X*$6M
M(SG@D<,>^C800@C%!_D=U55BU5NK!M3EHQGL7:AN0:Z<M.#<83-.[$O'MY^D
M8.^61&Q?'8_5T\,Q:T @GG_*B/X/N*/'[7HXL#5+DS7;^G<4&U+CU3S$AI4@
M+[N*"X(T"_$AZ>+SAIK@>(LM]*\Q9M<D2^3;3U)A3JE0PD-:KN@:1P@A%!_D
M=S2T9=75UJOA2/EHRHR(W(A([[2<X*4E5B#,KP@>E_*4?>^&>9&8VL</+SQM
M1)][17Q<_8T X:9>*[5L0JC*A2DNJD%%>2UJV)].-/\^JU<MI<>_2,><0:9&
M-<R8Y1R(H[O3D)]=3;MJ0@BA^"#7@_0N9Z96(C:L5&6('-F=BH]6QF#C_ B\
M.3D4KXXP8<%P$^8-,:G3=!F\'/:X$7WO=4//.]S@U%H/QY8Z.+2@>U93"AA\
M<W(8?OG18A4==0P6))I'##;$<CPGL](J E+5N\CNZZB%;9[$J;4.\X8&J;;5
M@MQJ_C$((83B@UP/597UZ@9$6K,2HLH0Y%4(PX4<Y2ASX5@F3A_,4&T.Q_:D
MX>#'*=BR*%IYZTNPEPPU][S+@,ZM=+900XJ/)I)L[HJ54\)P^82%P8)$\\BC
M*S>W9:4UR$@NQW>?IJJ;"'NO)7FG=6VK1Z^[W;!H5+#*%J'X((00B@_R!WS8
M98,J[5G2Q]S0GJ6JW-:F59A7 TN&39R<_=:,]]Z(QJS^@7BQDP^<'_" TVUZ
MJP#1-\K@)^O_%Q[R=U@U-1Q73S%8D#2/=Y2T#HK355),*0YL2U8S&/9>3W*H
M(L+#^4$/+)T8BC/?F%7;%R&$$(H/8M</?[T:7"\MJ46NI4KE1<@)X,YU\=BZ
M) ;_G!V!99-"L71"*-X8&X+71H7@E8$F3.GAAS$=KMV.W&F DU6<R$FB(]NS
M[%;2_B;AD5VM8O"MER/@<H;B@V@?.13)2*Z R5B <T?,*N-#W-SLO9[ZWN>.
M<<_Z8.'(8.S<D #W2WFJ39400@C%!['WQ[_6)D#D%D0V >$!12KEU_"SK3WK
MXG$+?CZ6A9^/9N'T03/V?Y",#Y?'8-74,'5".>PQ(WK<;D"7-OI?V[,H0.QP
M4GNK3J772[+YAKF1T)_+X<-+-(^$J0;[%.'XE^G8(EE%0TP8\HBGW=>3S+8M
M&1>*W9L2<?$'"R*#BE%1SG /0@BA^""-2H.#E@@2<=&24\G?EIP,1IJ*<?E$
M%O:]GX35T\/4D+HD;DL2<8,O/\7''U\B[B2C9<"#'MC\:I02AX1HG8JR.EP]
MDZV$Q]C./AC\J"=ZW&%HA*P<'WRX(A9N%W(1'UFFYN*8:DX((10?I(DAIY0R
M%!KB4XBKIRTXO"L5VU;&8=WL"*R9$:Y<F)9/#%56L$O&A6#1R&#,<@[ 1"=?
MC'C2B'Y_=5?N,BIYG0+EWVX3$2. F?T"5,:'GZ& #R31/'+C>O%X%M;,#%?"
M0YYS$=KV7D^3NOAAU_H$!'H6PIQ:@:*"&G7H0@@AA.*#-"'D-D3<LR19/3&J
M5(D0X^5<N)[-P=53%N7 =.D'"RY^GX7S1S*59__NC0G8."\2KXX(PIA.7NA^
MIPX=6UQ%1^:+_%LU]#$C9@\,Q+HY$>K_:WA ,1](HGDDE^BG[S*Q='PH>MWE
MAFYM#;;V33NOI\G=_?#ENTF(#BE1@^;E9;7*G(,00@C%!]$8TKHEH7=R2Y*9
M5@%OEUP<WYN&K4NB,7N0/_K>KT>G6Z["H:6+N@%QN#8C\C]+1]'QFQ+WL573
MPO'5^TFJ324QNHP/&]$\$HAZ<G\&Y@\+:M3U-*UW  Y^G(RTQ'+UKI+,'%I6
M$T((Q0?1J/AH" V3$\78L!)X7<G%F4,9^.+=!&Q<&(%5,\+4O,AJZV9ZY91P
MK)@4IDX^%X\.5CDCXJ@UJ:NT:GFA[WUN:J!=G)YNY%F2:;W]\?&J.+B<S4:8
M?Q$L&95\V(AFD5L&>4_(.T("_B3HM#%MJZ?W"< W.U)@3JE0AR5UG#4GA!"*
M#Z)M 2(?<_'OS\NN0GIB.6)"2A#@D0^WBSG6#;0%KM9-M-C%7CF9C0O'LG#V
M6UN;EOC\[WG;UJHU;V@@1CYM1/_V[E8!HK^AQ<?\8285P)8878IL<Z5J5R%$
MJ\B&O[*R3EE\?[\W'7,'FQHU+V=&WP#K>DI1+:0-89V$$$(H/LB-L FIKD=I
M<0WR<ZJ1$E^.</\B-4<BJ>M;%D5B9C\_C'S&*D ><%<9%UU:__>2&Q')&1$K
M6EO9+'^?;?E?N2/-0;0L'1^"2\>S5&L(VT.(UJE2J>:U,*=5X,AG:7AE8&"C
M" ]QXW-LZ8J7G0/5ORM"GA!"",4'N8&0U@M)7)?>[YRL*J0EE",VM$0)D%,'
M,O#YYGAL6QF+=UZ+QKK9D2I@KZ$D:T3<M5Y_,02OOA",N4."U*9B@I.M9:M_
M>P]E3]NEC<Z6T*XQ(2)S+_)[143)?Z<,\U-X$*TCC[#8=LNM0X2I&%^^EX29
MSP4V2E:.V/@ZW^^!U\>$J%D3L=@EA!!"\4%N(*3E05HPJJOJE.=_<4$-\J55
M*ZD"T2'%,'D6P%>7!Z\K><J3W^WG7!C.YZCZY4?+K^U:A[:G6(5*(K:OCE/"
M9-Y0$\8Z^&#(HY[H=;=!#;@[M-"6Q:\(#[G!D9L<F8N1_UY"FL.:EW:KV/ 2
M>%[.Q8ZU\9C2P]_NZTEN3@<^Z*DLJ^4=(8Y\<N-*""&$XH.0_Q-;VY%M V,[
M/:U 0E0I@GT*K1N9/%RR;M"__B@9FQ=%8^&(($SNX8=A3U@%R#T&]+S+H$X^
M98"]H;JWLY58?,KFI&L;6]E:NFSM7++Y=U1M7*Z-VL8EPD/^??D],I@O5L:$
M:!VY[93#!7_W ISYQJQ",R7TS][K2:Q\1SWCC=D# O'1BE@U<R8#[X000AJ1
M_P0  /__[=U9<%15 L9Q01%<41F789Q1Q\%Q(! 2EFB B&@DHD961004160)
M J6184 4@@H"HC**"@(1&603E'U)+]DZZ20DG7U/.IVDDW3VSMK=Z<][3J@9
MJWR8ITN9Z_>K.H^$%*>:NO^^9P'^KZM ]!OC]7J5 ;2W>=!8[T)-92>LA6W(
M2W<B/;$)^A,._+"[ M]\9,7VM478N"(/[[Z>@W<7Y&#M_&R\\VHVUKR2C=7S
MLK%J;A;>FIF)95/3L?AI"^8'I^*E1U+PPD-)F.9G1NC@!$S\:SS&#XQ%X&W1
M&'F# </[ZC'T:AU\>D5AR%7J#?]^>CQTBQ%!=\4HOW,.=#\Z./G4XWG<7F0D
M->'0SG)$A.5B_A.I>/R>.%4_2V(\^J=8O!Z2ALUOY>/8GDKY?T6KT\,)(2+Z
MC6%\T&\V0-S*0TQ'>Q?:6CQH;G2CWN&"P]X)6W$["C);Y -.:GPCS(9ZF"[6
M(?["Y7&^#C%G:F$\58NHXPZ<W%^%0U]58.]6*SY?5XS-X058MR@7;[^8B26A
M%KP\/@53AR<B^+XXC+T]&J-N,F!8'QV&*/&A9H"(OV?\P!@\]6 \/G@C#]&G
M&1_4\[DZNQ"M?/XVA^?CA< DA R*EY&M=GP\_6 "UBW,P9F#5<A*:8+=UJ[\
M+EY."!$1XX/HRH1+9T<7G,T>5)5WHC"K18:*\70M3AZHPH$=Y?CJ@Q(9(FM>
MS4;8LQ;,'IN,4)\$3+P_'H_\,0:! XP8,R :@;<9Y5N17XZ';S7*(1ZJ OHK
MXV8C1BLQ,>I&@WQ[(L:(ZPWPOTX/OWYZ^9;#KZ\>PZ_5*4,/7R5N@NZ,0>@0
M$^8$)>&S=PJ1H*OGY%&/)SYWIY3/V(KGTC'Z%N4S<+V^.^95CH_I_F;LB"A!
M0:83+4Z/_#VZNA@?1$2,#Z(KH*L+_WUSTE3O5@*D ]:"-N1:G$@S-<(450_=
M3P[YD'1D5P4BMUF5!Y=B;%M5B(_>S,?[2_,0L3@7ZQ?]>JP32[Q>RY%+NWZY
MK&O),Q:\-C$5\R9<PMR@%,P*3,9SH\R8YI>(*<,2\<S@!$QZP"27>3W^ES@\
M/SH)2R=;L'YQ#@[O+$=62C,GCGH\\9D[\9T=2Z=89'CX*L$MEC&J&1[B#>6,
M$69\_4$)2O):E=_!(Y=_>=D>1$2,#Z(K03QTB&\]/1[Q3:SW%TNW.N&P=\!N
MZX"MN VE^:WRK4ANFA.92<WR[<BEV$8D&1N09&B 65__JY&@A$OLV5H83CIP
M[D@UCD?:<>"+<NS98I7?O(J V;@B'^L6Y6"U$BAOS<K LFGI6'1YSXD(DYD!
M25@^/1U;P@N4/VM#W+E:E!6V<>)($_'QX[=V&>/#KHE2??^4_-G*>%X)?;$/
MK+RD7?G<>_G6@XB(\4&D#>+!1CQ@.9O<J%%"ID0)&/'6PJP$B^&4 V<.5>'8
MWDH<V&'#[JVE^/+]$GRZI@B;WBQ Q)(\N;D\?%8F/OYG(0Y_72[WJ^1G.%%7
MW<E_7.KAP0\9^C_LKL3")]-47VHEPL.GMPB<*'F(A-C7567KX&00$3$^B+1#
M?*/J=G4'B'B;XJCJ1$5I.TKRNI=UI9N;D!+;(/=PQ)RME:=SG3]:C=/?5^&G
M?7;Y8';PRW*<.UPM-\L79;>@NKQ#Q@Q13R4VFHOP$)^'[W>4R[=\:L?'4"4\
MQ/XIL;=JSKAD?/M)F1(?[9P,(B+&!Y%V_&])EU<^<+6W=<DC/46(--:Y4%?C
MDDN[JBNZEW=56MOE$B^QK$HL\RK.;97!82MJ0TUE!YKJ7?*A300-44_5UNI!
M0ZT+UL)61&XKPRL3+JD?'U=WA\?HFPURK]7^[3:YOXN(B!@?1$2DX2 7=_*(
M_1;BS9\XO&'.V&35XT.<'B=.G9MP=ZP\-OOPUQ7R7B B(F)\$!&1AN-#W*LA
M+O83AS!L7)XO3Y]2.S[$T=8A]\=CYD-)>&]A+LX<K$8M]TX1$3$^B(A(N\0R
M1+&<4.QOVK/5BI6SLQ Z.$'U^!#W\,P8F83E,S+PQ?H2Q)RMDTL?B8B(\4%$
M1)J-#R KN5F>WK9A22[F!U]"\+UQJL?'^(&Q6!"2ABUO%^)8I!V6Q":T-'LX
M(41$C \B(M(J<?B".#+ZLS6%F/=H,D('FS!F@%'U^!!+KE;/R\8/>RKE'3WB
M8 =Q"AT1$3$^B(A(J_'A]N+"T6JLFIN!H#OU".BOAU]?G>KQ,=DG 9_\JPAI
MID;4U72BU>F6(41$1(P/(B+2<'R<W&]'6.@E^/0ZKXP+2AQ<5/V"P6E^B=CY
M88D\MMKK9700$3$^B(CH=Q0?XE;S"Y>'6O&A_-Q>%^'3^R)FC%#B8V-W?! 1
M$>.#B(A^)_%QXCL1'Y;+T7%1U3<>(CR&7A.%&2,3L6M3B=SK041$C \B(M)X
M=(@-WLT-;AS=58&%D])4W^?ATSL*P_OJ,.(&'6:-,6/OQU9YN2$1$3$^B(A(
MPUJ='M14=J HIQ5[MY;AU<=258\/WSXZ!/0W(.@N(Q:$7,)_/K>ATLKX(")B
M?! 1D:;5.UPHS&Z!V=" [6N+,7M,LNKQX=]/CW%W&/'DH#@LGV[!D5WEJ+)U
M<#*(B!@?1$2D916E[4@R-N!X9"4B%N=ANK]9]?@8?9,!DQZ(QTN/)&-#6 [.
M'JJ"P][)R2 B8GP0$9&6%62VX,S!:OG68]G4=#SU=Y/J\3'V#]%X,3 )J^=E
M8>]6*Q*BZM%0Z^)D$!$Q/HB(2,LL"8W8]VD9PF=ERB57$^Z.53T^Q@^,0=BS
M%NR(*,;YH]7(37.BI=G#R2 B8GP0$9&6)>KJL?V=(LP9EXRG'S1AS(!HU>,C
M^-XXK'XY&\?V5,KX*2]I0WM;%R>#B(CQ041$6F8\Y<"&)7F8>'\<@NZ,P<@;
M#*K'QZ1!\?AP63[BSM7)/2>-=2ZX7;S=G(B(\4%$1)IVX6@-PE_(A/]U>@R_
M5H>A5^M4CX_0P0GX]]HBY*<[T=G1)>\:\;(]B(@8'T1$I#WB0=_C\<*M//2?
M/E E-YH/Z=5]\[AZMYHK8=.[.VZF^B;BJPTE*,WGK>9$1(P/(B+2-!$>KDZO
MW&?QTSX[EDZVR/!0-SZB,.P:'?SZZC!CA!D[/RQ5XJ.5DT%$Q/@@(B(M$_LK
MVEH]:&YTX_A>.\)"+:HOM1K:.TH)#SU&W6C S  SOME4"FL!XX.(B/%!1$2:
M)HZUM=O:49#5@LB/RS _.%7U^/#MH\/#MQKE4;ZOAZ1B_W8;;,5<=D5$Q/@@
M(B)-$[>)9Z4T0W^B!EM7%N#%P&35XT-L:'_LS[&8YF?&RME9\IA=>UD')X.(
MB/%!1$1:9BUL0_296NS[K RKYV7+#>!JQ\?HFPQXYA\)\BW+IA4%.'>X&M45
MC \B(L8'$1%I6JZE&<<C*[%Q11X6/96&D+_%JQX?XO+"N>-2\.Z"7.S[U"8O
M-ZQWN#@91$2,#R(BTK(T4R-V;R[%TLEI>&Z4&>,'QJ@>'X\.C,4;4]*Q:U,I
M#"=KD9_1 F>3FY-!1,3X("(B+3-=K,.6\'Q,\37A\7MB$=!?_5O-@^^-PWL+
M<G#^2#4*LUODOA-QP2 1$3$^B(A(PV+/UF)#6"Z>N"\&X^XP8M2->OCTCE)U
M3!H4CXW+\Q!_H4[N]1#'_+I=C \B(L8'$1%IFN&D VOG9V'L[08$]-=CQ/4Z
M^/:)4G6$#C9AVZH"I"<VR:-^.]J[T,7V(")B?! 1D;9%':_!RMD9\+\N"G[]
MKLR8,LR$'>N+4)3=P@D@(F)\$!$1XT.],=4W 5]&%#,^B(@TX&?RHCU*I?[[
-^0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
